VTGN News and Press, VistaGen Therapeutics Inc. From 09/08/22

Independent biostatisticians recommend continuing PALISADE-2 without any changes after conducting interim analysis of 140 completed subjects Topline data for PALISADE-2 trial expected in the first half of 2023 Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the...

Whether you call them penny stocks, cheap stocks, ground floor opportunities, or …lotto tickets, there’s no denying that low-priced stocks are lighting up the scanners and screeners this month. While many traders are trying to find the next round of multi-bagger stocks ready t...

Top Penny Stocks To Buy Penny stocks are defined as shares of companies that trade for less than $5. But when you look at the “real” penny stocks, many traders will tell you to look for stocks trading for pennies. Today, we look at a handful of penny stocks to buy for ...

VistaGen Therapeutics, Inc. (VTGN) Q1 2023 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Mark Flather – Vice President-Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer ...

Shares of micro-cap clinical-stage biopharmaceutical company VistaGen Therapeutics ( NASDAQ: VTGN ) fell 13% to $0.15 in Friday afternoon trading, after it reported a fall in quarterly revenue and a bottom line miss. South San Francisco, Calif.-based VTGN develops medici...

VistaGen Therapeutics (NASDAQ: VTGN ), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ...

VistaGen Therapeutics press release ( NASDAQ: VTGN ): Q1 GAAP EPS of -$0.10 misses by $0.02 . Revenue of $0.31M (-11.4% Y/Y) beats by $0.07M . Shares -10% . For further details see: VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue...

Evaluation of PALISADE-1 continues and interim analysis of PALISADE-2 begins Preliminary data from nearly 200 subjects in the PALISADE open label safety study suggest that continued as-needed use of PH94B has potential to achieve cumulative functional improvement in the severi...

VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and...

VistaGen Therapeutics, Inc . (NASDAQ: VTGN) a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and web...